
|Videos|June 9, 2014
Research into the Monoclonal Antibody GC33 for HCC
Author(s)Ghassan K. Abou-Alfa, MD
Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses two analyses of GC33 for the treatment of hepatocellular carcinoma (HCC).
Advertisement
Clinical Pearls
Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses two analyses of GC33 for the treatment of hepatocellular carcinoma (HCC).
- GC33 is a humanized monoclonal antibody against GPC3 that is frequently expressed in HCC.
- In aphase Ib dose escalation study, GC33 was looked at in combination with sorafenib. Though GC33 showed questionable tolerability, the agent will be looked at with a biomarker component in a future trial.
- Aphase II triallooking at GC33 in previously treated patients with HCC was also negative.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















